# SAB Biotherapeutics, Inc.: Form 8-K, filed Feb 5, 2025

- Company: [SAB Biotherapeutics, Inc.](/companies/sabs.md) (CIK 1833214)
- Form: 8-K
- Filed: 2025-02-05
- Accepted by EDGAR: Feb 5, 2025, 22:00 ET
- Period: 2025-01-30
- Accession: 0000950170-25-014627
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1833214/000095017025014627/sabs-20250130.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1833214/000095017025014627/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.01: Completion of an acquisition or disposition
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1833214/000095017025014627/sabs-20250130.htm

Filed Feb 5, 2025.
Source: SEC EDGAR, the filing index for accession 0000950170-25-014627. Last ingested by Listed: Oct 24, 2026, 14:57 ET. No prices; not investment advice.